ArticleJournal of Alzheimer's disease : JAD2018
A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER).
Article in Journal of Alzheimer's disease : JAD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Commercial volumetric MRI reporting tools in multiple sclerosis: a systematic review of the evidence.Neuroradiology · 2023Pooled it
- Grey matter changes on brain MRI in subjective cognitive decline: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a systematic review.Neuroradiology · 2021Pooled it
- Independent validation and outlier analysis of EuroPOND alzheimer's disease staging model using ADNI and real-world clinical data.Alzheimer's research & therapy · 2025Article
- AI-based staging, causal hypothesis and progression of subjects at risk of Alzheimer's disease: a multicenter study.Frontiers in neurology · 2025Article
- Automated Volumetric Software in Dementia: Help or Hindrance to the Neuroradiologist?AJNR. American journal of neuroradiology · 2024Article
- Brain age as a biomarker for pathological versus healthy ageing - a REMEMBER study.Alzheimer's research & therapy · 2024Article
- Integrated partially linear model for multi-center studies with heterogeneity and batch effect in covariates.Statistics · 2023Article
- Quantification of amyloid PET for future clinical use: a state-of-the-art review.European journal of nuclear medicine and molecular imaging · 2022Review
- Morphometric evaluation of traumatic axonal injury and the correlation with post-traumatic cerebral atrophy and functional outcome.The neuroradiology journal · 2022Article
- [Expert Opinions and Recommendations for the Clinical Use of Quantitative Analysis Software for MRI-Based Brain Volumetry].Taehan Yongsang Uihakhoe chi · 2021Review
- Morphological, Structural, and Functional Networks Highlight the Role of the Cortical-Subcortical Circuit in Individuals With Subjective Cognitive Decline.Frontiers in aging neuroscience · 2021Article
- Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer's Disease and Controls.Frontiers in aging neuroscience · 2021Article
- Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study.Journal of Alzheimer's disease : JAD · 2021Article
- Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.Molecular neurodegeneration · 2020Review
- Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia.Alzheimer's & dementia (New York, N. Y.) · 2020Article
- Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- andNeuroImage. Clinical · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMagnetic resonance imaging (MRI) acquisition/processing techniques assess brain volumes to explore neurodegeneration in Alzheimer's disease (AD).
objectiveWe examined the clinical utility of MSmetrix and investigated if automated MRI volumes could discriminate between groups covering the AD continuum and could be used as a predictor for clinical progression.
methodsThe Belgian Dementia Council initiated a retrospective, multi-center study and analyzed whole brain (WB), grey matter (GM), white matter (WM), cerebrospinal fluid (CSF), cortical GM (CGM) volumes, and WM hyperintensities (WMH) using MSmetrix in the AD continuum. Baseline (n = 887) and follow-up (FU, n = 95) T1-weighted brain MRIs and time-linked neuropsychological data were available.
resultsThe cohort consisted of cognitively healthy controls (HC, n = 93), subjective cognitive decline (n = 102), mild cognitive impairment (MCI, n = 379), and AD dementia (n = 313). Baseline WB and GM volumes could accurately discriminate between clinical diagnostic groups and were significantly decreased with increasing cognitive impairment. MCI patients had a significantly larger change in WB, GM, and CGM volumes based on two MRIs (n = 95) compared to HC (FU>24months, p = 0.020). Linear regression models showed that baseline atrophy of WB, GM, CGM, and increased CSF volumes predicted cognitive impairment.
conclusionWB and GM volumes extracted by MSmetrix could be used to define the clinical spectrum of AD accurately and along with CGM, they are able to predict cognitive impairment based on (decline in) MMSE scores. Therefore, MSmetrix can support clinicians in their diagnostic decisions, is able to detect clinical disease progression, and is of help to stratify populations for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.